Displaying drugs 501 - 525 of 8033 in total
Mobocertinib
Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the EGFR gene, which are typically associated with a poorer prognosis (as compared to "classical" EGFR mutants...
Approved
Investigational
Matched Description: … It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion ... [A238828] Mobocertinib appears to be an effective means of treating this otherwise treatment-resistant ... Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of …
Glucagon
Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.[L7634,L7637,L7640,L7643,L8519] Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.[L7640,L7643]
Glucagon was granted FDA...
Approved
Matched Description: … , stimulating glycogenolysis and the release of glucose. ... amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of ... [L7634,L7637,L7640,L7643,L8519] Glucagon raises blood sugar through activation of hepatic glucagon receptors …
Milrinone
Heart failure is a multifactorial condition that affects roughly 1-2% of the adult population. Often the result of long-term myocardial ischemia, cardiomyopathy, or other cardiac insults, heart failure results from an inability of the heart to perfuse peripheral tissues with sufficient oxygen and metabolites, resulting in complex systemic pathologies. Heart...
Approved
Matched Description: … Heart failure is a multifactorial condition that affects roughly 1-2% of the adult population. ... Often the result of long-term myocardial ischemia, cardiomyopathy, or other cardiac insults, heart failure ... second-generation bipyridine phosphodiesterase (PDE) inhibitor created through chemical modification of …
Erlotinib
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)...
Approved
Investigational
Matched Description: … in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. ... This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and ... of patients with idiopathic myelofibrosis or essential thrombocythemia. …
Omega-3-carboxylic acids
The omega-3 carboxylic acid (OM3-CA) is a new formulation of omega-3 fatty acids that present an enhanced bioavailability in the treatment of dyslipidemia. The increased bioavailability is explained because OM3-CA is found in a form of polyunsaturated free fatty acids as opposed to other products whose form is as ethyl...
Approved
Investigational
Matched Description: … The rest of the concentration is represented by docosapentaenoic acid and traces of some other components ... bioavailability in the treatment of dyslipidemia. ... acid as the most abundant species found in a proportion of 55% and 20% respectively. …
Curcumin
Curcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in Curcuma xanthorrhiza oil. It is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglycemic, antioxidant, wound-healing, and antimicrobial activities . Due to these properties, curcumin has been investigated for the treatment and...
Approved
Investigational
Matched Description: … Curcumin is under investigation for the treatment and supportive care of various clinical conditions ... Due to these properties, curcumin has been investigated for the treatment and supportive care of clinical ... rapid metabolism, and rapid systemic elimination have been shown to limit the therapeutic efficacy of …
Tenecteplase
Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids...
Approved
Matched Description: … It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine ... Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA …
Rupatadine
Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing in Canada under the tradename Rupall and comes in tablet formulation for adult use and...
Approved
Prednisone
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver. Prednisone was granted FDA approval on 21 February 1955.
Approved
Vet approved
Agalsidase beta
Agalsidase beta is a recombinant human α-galactosidase A similar to agalsidase alfa. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa,...
Approved
Investigational
Matched Description: … [A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after …
Albendazole
A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)
Approved
Vet approved
Estazolam
A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam.
Approved
Illicit
Scorpion (centruroides) immune Fab2 antivenin (equine)
Centruroides (scorpion) Immune F(ab')2 (equine) is a purified preparation of immune globulin F(ab’)2 fragments that are derived from plasma of the horses immunized with venom of C. noxius, C. l. limpidus, C. l. tecomanus, and C. s. suffusus. It is intravenously administered patients with clinical signs of scorpion envenomation so...
Approved
Matched Description: … fragments that are derived from plasma of the horses immunized with venom of *C. noxius*, *C. l. limpidus ... Centruroides (scorpion) Immune F(ab')2 (equine) is a purified preparation of immune globulin F(ab’)2 ... It is intravenously administered patients with clinical signs of scorpion envenomation so that the Fab …
Agalsidase alfa
Agalsidase alfa is a recombinant human α-galactosidase A similar to agalsidase beta. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa,...
Approved
Matched Description: … [A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after …
Zaleplon
Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States.
Approved
Illicit
Investigational
Matched Description: … Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of …
Teriflunomide
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and...
Approved
Matched Description: … Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting ... The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients ... It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically …
Levamlodipine
Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of amlodipine, an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlodipine and levamlodipine may be used interchangeably as both...
Approved
Investigational
Matched Description: … [L10833] Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. ... Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], …
Nitroprusside
Nitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). Nitroprusside is often administered intravenously to patients who are experiencing a hypertensive emergency.
Approved
Investigational
Matched Description: … Nitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles …
Terbutaline
Terbutaline was first synthesized in 1966 and described in the literature in the late 1960s and early 1970s. It is a selective beta-2 adrenergic agonist used as a bronchodilator in asthmatic patients.[A230333,L32093,L32098]
Terbutaline was granted FDA approval on 25 March 1974.
Approved
Avapritinib
Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers. Avapritinib shares a...
Approved
Investigational
Matched Description: … [A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant ... Avapritinib, or BLU-285,[A189327] is a selective tyrosine kinase inhibitor of KIT and platelet derived ... growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal …
Dexbrompheniramine
Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.
Approved
Matched Description: … Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions …
Oritavancin
Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of...
Approved
Investigational
Matched Description: … of [vancomycin] therapy. ... Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. ... [A39384,A193482,L8492]
On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in …
Bilastine
Bilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.
Approved
Investigational
Matched Description: … antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of …
Fondaparinux
Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in heparin and HS...
Approved
Investigational
Matched Description: … a O-methyl group at the reducing end of the molecule. ... ); and in the management of ST segment elevation myocardial infarction (STEMI). ... Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and …
Hydralazine
Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed. Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure.[A186820,L8782,L8785] Hydralazine is no longer a...
Approved
Matched Description: … hypertension and only as adjunct therapy in the treatment of heart failure. ... Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of ... L8782,L8785] Hydralazine is no longer a first line therapy for these indications since the development of …
Displaying drugs 501 - 525 of 8033 in total